Challenges for the FDA: The Future of Drug Safety, Workshop by Leslie A. Pray, Sally Robinson

By Leslie A. Pray, Sally Robinson

Show description

Read or Download Challenges for the FDA: The Future of Drug Safety, Workshop Summary (Forum on Drug Discovery, Development, and Translation) PDF

Similar health policy books

HEALTH POLICY

The future health care process in Britain at the start of the twenty-first century is being subjected to radical rethinking. overall healthiness coverage examines how the NHS has constructed to the purpose it has reached this day in addition to putting it within the wider context of the types of healthiness care that are to be had to humans in Britain.

Street Science: Community Knowledge and Environmental Health Justice (Urban and Industrial Environments)

While environmental illnesses come up in a group, policymakers needs to be capable of reconcile the first-hand adventure of neighborhood citizens with thoughts via scientists. during this hugely unique examine environmental health and wellbeing policymaking, Jason Corburn indicates the ways in which neighborhood wisdom could be mixed with expert suggestions to accomplish larger options for environmental overall healthiness difficulties.

Economics of Health Care Financing: The Visible Hand

This re-creation examines the economics of well-being care platforms in a non-technical demeanour. it truly is written in a hugely obtainable demeanour for economists and non-economists alike. it's very well timed and contains the most recent facts of future health care reforms and their implications from a couple of international locations with diverse structures.

Extra resources for Challenges for the FDA: The Future of Drug Safety, Workshop Summary (Forum on Drug Discovery, Development, and Translation)

Example text

Once pilot programs have been assessed, the agency will be better equipped to make that decision. Further, he emphasized that whoever has responsibility for sign-off, the postmarket review and assessment, as well as any revisions to labeling, must involve clinical judgment and understanding of both the risks and benefits of the therapy. Dr. Unger expressed his impression that there is not a great deal of clinical experience within OSE, and that OSE would need to expand its resources to include clinicians who understand both risk and benefit.

Therefore, Dr. McClellan suggested that the acquisition of better data and the implementation of a systematic strategy for analysis will require additional support for postmarket surveillance, the development of a comprehensive implementation plan, and effective public–private collaboration to carry it out. Dr. ” The consortium could be an important component of a national active surveillance system that would include other data sources. As Dr. Tilson noted, the CERTs were created under congressional mandate and have robust processes that already make them good hosts for a public–private partnership.

2 billion. eps billion. SOURCE: Coalition for a Stronger FDA, 2007. committees are unsympathetic to the agency’s drug safety mission, but because the majority of resources are consumed by the agricultural sector. ” Industry User Fees Mary Pendergast, President, Pendergast Consulting, asserted that since the authorization of PDUFA in 1992, Congress has increasingly relied on user fees rather than congressional appropriations to fund the ADDRESSING THE FDA’S RESOURCE CHALLENGES 17 FDA, a situation that contrasts with the funding provided to CDC and NIH.

Download PDF sample

Rated 4.31 of 5 – based on 10 votes

Categories: Health Policy